Shades of Survivorship

Elyse R. Park, PhD, MPH; Jeffrey Peppercorn, MD, MPH; and Areej El-Jawahri, MD

The 2006 Institute of Medicine (IOM) report, “From Cancer Patient to Cancer Survivor: Lost in Transition,” acknowledges the differences in the meaning of the term survivor. Historically, to signify a period of decreased mortality risk, the definition for a cancer survivor delineated a 5-year disease-free benchmark. However, in 1986, to empower patients and their family members to embrace their cancer experience, the National Coalition for Cancer Survivorship (NCCS) defined a cancer survivor as a person diagnosed with cancer, beginning at the time of diagnosis. Over the past decade since the IOM report, efforts have been made to further define—and develop categories for—survivorship, including articles by Azize, who emphasized the importance of incorporating late and long-term effects into definitions, and Surbone, who proposed 4 categories of survivors: acute, chronic, long term, and cured. The lack of an agreed upon formulation of survivorship and its phases has consequences for patients, clinicians, health systems, and research.

The NCCS definition, although widely adapted, has pitfalls. The first is confusion, due to heterogeneity in treatment stage and risk of recurrence or progression. It thereby creates an ambiguity regarding what being designated a “survivor” conveys in terms of prognosis. The second issue is the psychological pressure that patients feel to embody the term survivor and perpetuate an image of strength, which may conflict with their feelings and perspectives on their disease. Third, patients receiving active cancer therapy and those living with cancer may feel ambivalent about being labeled a survivor.

Moreover, embracing this term can be problematic for differing reasons during a patient’s illness trajectory. At diagnosis, patients often feel an “imposter syndrome” associated with the use of the term survivor. As they receive active cancer-directed therapy, they may feel guilty for not exuding the strength they associate with a cancer survivor. Lastly, patients living with metastatic cancer may feel frustrated with the survivor terminology, because it sets unrealistic expectations.

The needs of patients with cancer differ during the various phases of their illness (Table 1). Using more nuanced terms to describe patients during these phases may provide a more realistic and individualized approach to addressing these needs. Newly diagnosed patients with cancer receiving curative therapy, patients who complete active therapy with curative intent, and those living with cancer have distinct supportive and palliative care needs. Thus, grouping these patients collectively as cancer survivors obscures the unique challenges each faces at different phases of the cancer care trajectory.

From a healthcare system and clinician perspective, it is critical to recognize patients’ discrete care coordination need based on their illness phase. In newly diagnosed patients, oncology clinicians are responsible for care, with frequent appointments for evaluation and delivery of cancer-directed therapy and symptom management. In patients who have completed active therapy, oncology clinicians often manage long-term effects of therapy but facilitate care transition to primary care with an emphasis on cancer prevention, health maintenance, and monitoring for late effects. In contrast, for patients living with cancer, oncology clinicians often collaborate with palliative care specialists to optimize quality of life, manage complex symptoms, and enhance patients’ understanding of their illness and prognosis.

doi: 10.6004/jnccn.2018.7071

The ideas and viewpoints expressed in this commentary are those of the author and do not necessarily represent any policy, position, or program of NCCN.
Clinical issues, such as emotional distress, pain control, or symptom management, are not restricted to a single phase of care. These may be best addressed with programs and/or guidelines for all patients, organized under the broader heading of “supportive care services.” Other issues, ranging from initial care navigation, to transition to primary care, to discussions of end-of-life preferences, require distinct focus within a given phase of care. Viewing all aspects of cancer care as “survivorship care” complicates recognition of these important distinctions and delivery of appropriate care to patients within each distinct phase.

Given the confusion that can be caused by and the psychological implications of the term survivor; the unique supportive care needs of patients with cancer, which vary by illness phase; and the healthcare system and research challenges associated with a uniform definition of survivor, it is time to adopt a more individualized and patient-centered approach to identify and address the unique experiences of patients with cancer in each phase of illness. Dr. Fitzhugh Mullan, a pioneer in cancer survivorship work, reflected on his own cancer experience and posited that there are relatively predictable stages of survival: (1) an acute phase, from time of diagnosis through the end of initial cancer therapy; (2) extended survivorship, beginning at the end of initial cancer therapy through follow-up examinations and consolidative or maintenance therapy; and (3) permanent survivorship, occurring years after cancer treatment, when recurrence seems less likely. ASCO has largely adapted this framework in its characterization of cancer survivorship. However, there is need for further refinement and dissemination of this framework, particularly with advances in cancer therapeutics that can blur the lines between phases of care. Indeed, with the recent advancements in targeted therapies, hormonal therapies, and immunotherapy,
it is difficult to ascertain when treatment ends. Furthermore, even the phases of survivorship delineated previously do not include individuals living with metastatic disease with prolonged life expectancy who are continuing to receive noncurative therapies.

Patients newly diagnosed with cancer who are receiving active therapy with curative intent may benefit from a more nuanced term to describe their concerns and needs. Alternatively, patients who complete active therapy with curative intent may find the term survivor useful to characterize supportive care needs, such as the transition from acute oncologic care to less frequent and more wellness-based care, management of the physical and emotional sequelae of cancer, and screening for late effects. Patients living with cancer and receiving ongoing life-extending therapies have important palliative care needs, and the term cancer survivor may suggest unrealistic expectations. Thus, it is imperative to begin a discussion regarding nomenclature recommendations that would accurately depict the distinct phases of the journey for patients with cancer—from diagnosis to end of life—that would honor and capture the essence of their experiences.

References